Podzamczer D, Rozas N, Domingo P, Ocampo A,Van den Eynde E, Vergara A, Deig E, Knobel H, Pasquau J, Antela A, Crespo M, Clotet B, Geijo P, Rodríguez de Castro E, Casado A
Clinical Data And Patient-Reported Outcomes (PRO) In HIV-Infected Adults Switching To RPV/FTC/TDF, Due To A Previous Intolerance To cART. Interim Analysis Of The PRO-STR Study
VII Congreso Nacional de Gesida. Madrid, Spain. 1-4 dic 2015
Podzamczer D, Rozas N, Domingo P, Ocampo A,Van den Eynde E, Vergara A, Deig E, Knobel H, Pasquau J, Antela A, Crespo M, Clotet B, Geijo P, Rodríguez de Castro E, Casado A
Clinical Data And Patient-Reported Outcomes (PRO) In HIV-Infected Adults Switching To RPV/FTC/TDF, Due To A Previous Intolerance To cART. Interim Analysis Of The PRO-STR Study
15th European AIDS Conference (EACS). Barcelona, Spain. 21-24 oct 2015
Ocampo A, Domingo P, Fernández P, Diz J, Barberá JR, Sepúlveda MA, Salgado X, Rodriguez M, Santos J, Yzusqui M, Castaño M, Lorenzo JF, Bahamonde A, Bachiller P, Martínez E, Rozas N, Torres C, Muñoz A, Podzamczer D
Lipid Changes And Tolerability In A Cohort Of Adult HIV-infected Patients Switching To RPV/FTC/TDF, Due To Intolerance To Previous cART. A Substudy Of PRO-STR Study
15th European AIDS Conference (EACS). Barcelona, Spain. 21-24 oct 2015
Ventura Cerdá JM, Martín Conde MT, Morillo Verdugo R, Yébenes Cortés M, Casado Gómez MA
Adherencia, satisfacción y calidad de vida relacionada con la salud en pacientes infectados por el VIH con tratamiento antirretroviral en España. Estudio ARPAS
Farm Hosp. 2014;38(4):291-9
Pérez-Valero I, Martín-Quirós A, Roldán C, Díaz M, Torres C, Bernardino JI, Zamora FX, Pascual F, Arribas JR, González L, Herrero A, Casado MA, De La Puente M, González-Garcia J
Estudio de Coste-Efectividad de las estrategias terapéuticas actuales de simplificación del tratamiento antrirretroviral-Estudio Gesida 6911 a
V Congreso Nacional GeSIDA. Sitges, España. 19-22 nov 2013
Homar F, Lozano V, Martínez-Gómez J, Oyagüez I, Pareja A, Payeras A, Serrano J, Carmen Carratalá, Casado MA
Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs
Health Econ Rev. 2012,2:16
Homar F, Lozano V, Oyagüez I, Casado MA
Cost analysis of antiretroviral treatment and drug-related adverse events of fixed-dose combinations of antiretrovirals versus separate components in HIV-1 therapy
17th Congress of European Association of Hospital Pharmacist (EAHP). Milan, Italy. 21-23 mar 2012
Moreno S, González J, Lekander I, Martí B, Oyagüez I, Sánchez-de la Rosa R, Casado MA
Effectiveness of Maraviroc Plus Optimized Background Therapy for Previously Treated Patients with R5 HIV-1 Infection From the Perspective of the Spanish Health Care System
Clin Therap. 2010;32(13):2232-45
Oyagüez I, Casado MA, Cotarelo M, Ramírez-Arellano A, Mallolas J